“For the world’s poorest people – the roughly 1 billion living on less than US$1.25 per day – diabetes represents a different challenge. Located predominantly in sub-Saharan Africa and south Asia, the poor are mostly subsistence farming families with very low rates of obesity. As a result, the poorest billion are less likely to have typical type 2 diabetes. Instead, they have long endured a weakly documented burden of type 1 diabetes […] The scarcity of diagnosis and treatment for relatively rare, complex, and inadequately researched disorders, such as diabetes, is an endemic emergency for the poor.”
In this commentary, investigators from Partners In Health – including NCD Synergies’ Dr. Gene Bukhman – University of Rwanda, Rwanda Diabetes Association, Boston University, and University of Geneva, outline the importance of researching and addressing the burden of diabetes specific to the world’s poorest populations in low-income countries.
The commentary, published in The Lancet Diabetes & Endocrinology in June 2015, also discusses the following organizational initiatives in type 1 Diabetes, supported by Helmsley Charitable Trust:
- An integrated NCD clinical and policy collaboration led by Partners In Health to address health system constraints to care for complex chronic disorders such as type 1 diabetes at the district hospital level in Haiti and Rwanda.
- The “Addressing the Challenge and Constraints of Insulin Sources and Supply (ACCISS)” study, led by Health Action International, Boston University School of Public Health, and University of Geneva, to investigate the barriers in access to insulin in low-income countries. ACCISS researchers will focus on better understanding the global insulin market and current insulin access programs, developing innovative models of supply, and developing an advocacy network to eliminate barriers to worldwide insulin access.